首页> 外文期刊>Internal medicine journal >Early prosthetic hip joint infection treated with debridement, prosthesis retention and biofilm-active antibiotics: Functional outcomes, quality of life and complications
【24h】

Early prosthetic hip joint infection treated with debridement, prosthesis retention and biofilm-active antibiotics: Functional outcomes, quality of life and complications

机译:清创,假体保留和生物膜活性抗生素治疗的早期人工髋关节感染:功能预后,生活质量和并发症

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Patients treated for early prosthetic joint infection (PJI) with surgical debridement, prosthesis retention and biofilm-active antibiotics, such as rifampicin or fluoroquinolones have a rate of successful infection eradication that is similar to patients treated with the traditional approach of prosthesis exchange. It is therefore important to consider other outcomes after PJI treatment that may influence management decisions, such as function, quality of life (QOL) and treatment-associated complications. Aims:: To describe rates of successful treatment for patients with PJI undergoing surgical debridement, prosthesis retention and biofilm-active antibiotics and compare their functional outcomes, QOL and complication rates to patients without PJI. Methods:: Nineteen patients treated for PJI after hip arthroplasty with debridement, prosthesis retention and biofilm-active antibiotics were matched to 76 controls who underwent hip arthroplasty with no infection. Results:: Cumulative survival free from treatment failure at 2 years was 88% (95% confidence interval, 59-97%). PJI cases had significant improvement from pre-arthroplasty to 12-months post-arthroplasty in function according to Harris Hip Score and QOL according to the 12-item Short Form Health Survey Physical Component Summary. There was no significant difference in the improvement between controls and cases. PJI was not a risk factor for poor function or QOL. Medical complications occurred more frequently in cases (6/19 (32%)) than controls (9/76 (12%); P = 0.04), with this difference being accounted for by drug reactions. Surgical complications were the same in the two groups. Conclusions: Treatment of PJI with debridement, prosthesis retention and biofilm-active antibiotics is successful, well tolerated and results in significant improvements in function and QOL, which are similar to patients without PJI.
机译:背景:通过手术清创,假体保留和生物膜活性抗生素(如利福平或氟喹诺酮)治疗的早期假肢关节感染(PJI)的患者,根除成功感染的率与采用传统假体置换方法治疗的患者相似。因此,重要的是考虑PJI治疗后可能影响管理决策的其他结局,例如功能,生活质量(QOL)和与治疗相关的并发症。目的:描述外科手术清创,假体保留和生物膜活性抗生素治疗的PJI患者的成功治疗率,并比较无PJI的患者的功能结局,生活质量和并发症发生率。方法:将19例接受髋关节置换术,清创,假体保留和生物膜活性抗生素治疗的PJI患者与76例接受了髋关节置换术且无感染的对照组相匹配。结果:2年无治疗失败的累积生存率为88%(95%置信区间59-97%)。根据Harris髋关节评分和QOL(根据12个项目的简短形式健康调查身体成分摘要),PJI病例的功能从人工置换术到置换后的12个月有明显改善。对照和病例之间的改善没有显着差异。 PJI不是功能差或QOL的危险因素。病例(6/19(32%))比对照组(9/76(12%); P = 0.04)更容易发生医疗并发症,这种差异是由药物反应引起的。两组的手术并发症相同。结论:通过清创,假体保留和生物膜活性抗生素治疗PJI是成功的,耐受性良好的,其功能和QOL显着改善,与无PJI的患者相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号